Staphylococcus lugdunensis: Difference between revisions
No edit summary |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
*A [[Gram Positive Bacteria]] | *A [[Gram Positive Bacteria]] | ||
*Causes [[endocarditis]], [[meningitis]], and [[Skin and Soft Tissue Infections]] | *Causes [[endocarditis]], [[meningitis]], and [[Skin and Soft Tissue Infections]] | ||
Antibiotic susceptibility pattern of 540 Staphylococcus lugdunensis isolates tested with the disc diffusion method:<ref>Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647525/ Accessed 21 December 2020.]</ref> | |||
{| class="wikitable sortable" | |||
|- | |||
! Antibiotic !! No. (%) susceptible | |||
|- | |||
| Penicillin G || 403 (74.6) | |||
|- | |||
| Gentamicin || 538 (99.6) | |||
|- | |||
| Rifampicin || 538 (99.6) | |||
|- | |||
| Cefoxitin || 538 (99.6) | |||
|- | |||
| Fusidic acid || 528 (97.8) | |||
|- | |||
| Trimethoprim/sulfamethoxazole || 539 (99.8) | |||
|- | |||
| Norfloxacin || 539 (99.8) | |||
|- | |||
| Clindamycin || 494 (91.5) | |||
|- | |||
| Erythromycin || 506 (93.7) | |||
|- | |||
|} | |||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2010</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2010</ref>== | ||
===Key=== | ===Key=== | ||
{{Template:Antibacterial Spectra Key}} | {{Template:Antibacterial Spectra Key}} | ||
Latest revision as of 19:27, 21 December 2020
Background
- Staphylococcus lugdunensis is a coagulase-negative staphylococcus with unusual pathogenicity resembling that of S. aureus[1]
- A Gram Positive Bacteria
- Causes endocarditis, meningitis, and Skin and Soft Tissue Infections
Antibiotic susceptibility pattern of 540 Staphylococcus lugdunensis isolates tested with the disc diffusion method:[2]
| Antibiotic | No. (%) susceptible |
|---|---|
| Penicillin G | 403 (74.6) |
| Gentamicin | 538 (99.6) |
| Rifampicin | 538 (99.6) |
| Cefoxitin | 538 (99.6) |
| Fusidic acid | 528 (97.8) |
| Trimethoprim/sulfamethoxazole | 539 (99.8) |
| Norfloxacin | 539 (99.8) |
| Clindamycin | 494 (91.5) |
| Erythromycin | 506 (93.7) |
Antibiotic Sensitivities[3]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
Table Overview
| ||||||||||||||||||||||||||||||||||||||||
See Also
References
- ↑ Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. Accessed 21 December 2020.
- ↑ Taha L, Stegger M, and Soderquist B. Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options, European Journal of Clinical Microbiology & Infectious Diseases, May 2019. Accessed 21 December 2020.
- ↑ Sanford Guide to Antimicrobial Therapy 2010